Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2025-11-05 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection Method from Two Clinical Trials at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting - Attachment: 251
Regulatory Filings Classification · 100% confidence The document is a press release from Nykode Therapeutics announcing the presentation of clinical trial data at a medical conference (SITC 2025). It provides highlights of the research findings and mentions that the poster will be available on their website. As it is a general corporate announcement regarding research and development activities that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing/announcement.
2025-11-05 English
Nykode Therapeutics to Present Data on the Strength of the Neoantigen Selection Method from Two Clinical Trials at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting
Regulatory Filings Classification · 100% confidence The document is a press release announcing the presentation of clinical trial data at a scientific conference (SITC 2025). It details the results of the NeoSELECT platform and clinical trials VB N-01 and VB N-02. Since this is a general corporate announcement regarding research and development progress and does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the general regulatory announcement category.
2025-11-05 English
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. Patent for the Neoantigen Selection Method for VB10.NEO, Nykode’s Individualized Neoantigen Therapy - Attachment: 251104 N
Regulatory Filings Classification · 100% confidence The document is a corporate announcement regarding the issuance of a new U.S. patent for the company's proprietary technology (NeoSELECT platform). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory/corporate announcement regarding business operations and intellectual property, it falls under the fallback category of Regulatory Filings (RNS).
2025-11-04 English
Nykode Therapeutics Strengthens Intellectual Property Portfolio with New U.S. Patent for the Neoantigen Selection Method for VB10.NEO, Nykode’s Individualized Neoantigen Therapy
Regulatory Filings Classification · 100% confidence The document is a press release announcing the issuance of a new U.S. patent for the company's proprietary technology (NeoSELECT platform). It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a specific corporate action like a dividend or share issue. As it is a general corporate announcement regarding intellectual property, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2025-11-04 English
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: CGC_212269179_Nykode_Therapeutics_ASA_42591_Filing.fo (1).pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification from The Capital Group Companies, Inc. to Nykode Therapeutics ASA and the Oslo Stock Exchange regarding the acquisition of shares that resulted in the firm crossing a 5% ownership threshold. This is a classic 'Major Shareholding Notification' (often referred to as a TR-1 or similar disclosure in various jurisdictions) used to report changes in significant share ownership levels.
2025-10-14 English
Disclosure of Large Shareholding - Nykode Therapeutics ASA - Attachment: SCWF_26102_3401_212269179_Nykode_Therapeutics_ASA_42592_Filing.fo.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification from SMALLCAP World Fund, Inc. to Nykode Therapeutics ASA and the Oslo Stock Exchange regarding the acquisition of shares that resulted in the fund crossing a 5% ownership threshold. This is a classic 'Major Shareholding Notification' (often referred to as a TR-1 form in some jurisdictions or a disclosure of large shareholdings). It explicitly mentions 'Disclosure of acquisition/disposition of large shareholdings' in the subject line and provides detailed transaction and holding schedules.
2025-10-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.